logo-loader

Introducing the analyst: Christopher Ecclestone

Published: 10:08 22 Nov 2019 EST

Prior to founding Hallgarten & Company in 2003, Christopher was the head of research at an economic thinktank in New Jersey. He was also founder and head of research at the esteemed
Argentine equity research firm, Buenos Aires Trust Company. 

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

3 hours, 47 minutes ago